LifeStance Health Group, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; it does not provide a separate, clearly stated fourth-quarter financial summary. Amounts below are in U.S. dollars and, unless noted, millions.
Business context
LifeStance operates an outpatient mental-health platform offering in-person and virtual care. At year-end it employed 5,631 clinicians across 33 states and operated 619 centers. In 2022, clinicians served over 680,000 unique patients through approximately 5.7 million visits. Revenue is primarily generated per visit through insurance reimbursement; 91% of revenue came from commercial in-network payors, 4% from government payors, 4% from self-pay and 1% from non-patient services.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Revenue | $859.5 | $667.5 | Up 29%; increase was primarily attributed to higher patient visits. |
| Center Margin (non-GAAP) | $237.0 | $201.5 | Up 18%; approximately 27.6% of revenue versus 30.2%. |
| Operating loss | $(210.2) | $(286.4) | Loss narrowed; approximately (24.5)% of revenue versus (42.9)%. |
| Net loss | $(215.6) | $(307.2) | Loss narrowed; diluted loss per share was $(0.61), versus $(1.05). |
| Adjusted EBITDA (non-GAAP) | $52.7 | $49.2 | Up 7%; approximately 6.1% of revenue versus 7.4%. |
| Cash from operating activities | $52.8 | $9.4 | Improved year over year. |
| Cash and cash equivalents | $108.6 | $148.0 | Down $39.4 during 2022. |
| Debt principal outstanding | $234.0 | $161.2 | Year-end 2022 balance; $225.1 net carrying amount after unamortized costs. |
Center Margin and Adjusted EBITDA are non-GAAP measures and exclude costs that remain important to the business; they should not be treated as GAAP profitability. Center costs rose 34% to $622.5 million, reflecting higher clinician compensation, visits and occupancy costs. General and administrative expenses fell 13% to $378.0 million, mainly because 2021 included substantial IPO-related stock compensation; 2022 stock-based compensation was still $187.4 million.
Investing activities used $139.5 million, including $60.2 million for acquisitions and $79.3 million for property and equipment. Management stated that cash on hand was expected to fund operating and capital needs for at least 12 months from issuance of the financial statements, without additional financing. Year-end operating lease liabilities were $251.4 million; undiscounted minimum lease payments totaled $299.9 million.
Material changes, outlook and risks
- Revenue growth reflected increased visits, while center costs grew faster than revenue. Despite positive Adjusted EBITDA and operating cash flow, the company remained significantly loss-making under GAAP.
- In May 2022, the company refinanced its prior credit agreement with a new facility. It had $234.0 million of debt principal outstanding at year-end, no revolving borrowings, and reported compliance with its financial covenants. A $50 million revolving facility and up to $100 million delayed-draw term facility were available under the agreement. The company entered an interest-rate swap covering approximately 94.5% of its term loan exposure, with the stated aim of reducing SOFR-related cash-flow variability.
- No specific numerical FY2023 revenue, earnings or cash-flow guidance is provided in the supplied filing text. Management describes clinician recruiting, center openings, acquisitions, existing-center growth and integrated-care partnerships as growth priorities, while noting that investment needs and seasonal business-day patterns may affect results.
- Two payors, UnitedHealthcare and Anthem, represented 19% and 14% of 2022 revenue, respectively. Changes to their reimbursement rates, coverage or network participation could materially affect results.
- Management reported that disclosure controls and internal control over financial reporting were ineffective at December 31, 2022. Previously identified material weaknesses in accounting/finance resources, financial reporting controls and IT general controls remained unremediated, although remediation work was ongoing. The company also disclosed a prior restatement of 2018 and 2019 financial statements relating to acquired intangible assets.
- A shareholder class action filed in August 2022 alleges IPO registration-statement misstatements or omissions concerning patient visits and clinician retention. The company had not recorded a material accrual and stated that the outcome and any loss range could not be predicted or estimated.
- Other notable risks include clinician recruitment and retention, healthcare regulation and corporate-practice-of-medicine restrictions, telehealth rules, privacy and cybersecurity, competition, lease commitments, and the company’s controlled-company structure. The CEO and CFO transitioned during 2022.
Key facts for investors to verify
- Whether visit growth, clinician hiring and retention, and center productivity support growth without further margin pressure.
- Payor concentration and reimbursement trends, particularly with UnitedHealthcare and Anthem, and the durability of virtual/in-person rate parity.
- Cash generation relative to capital spending, acquisition commitments, lease payments, debt service and available credit facilities.
- Progress in remediating the material weaknesses and whether management’s financial reporting controls become effective.
- Developments in the IPO-related class action and any other regulatory, reimbursement, privacy or compliance matters.
- The assumptions and exclusions behind Center Margin and Adjusted EBITDA, including substantial stock-based compensation.